References: 1. Fietz M et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab. 2016;119:160–167. 2. Schulz A et al. Biochim Biophys Acta 2013;1832:1801–1806. 3. Mole SE et al. Neurogenetics. 2005;6:107–126. 4. Pérez-Poyato MS et al. J Child Neurol 2013;28:470–478. 5. Chang M et al. CLN2. In: Mole S, Williams R, and Goebel H, eds. The neuronal ceroid lipofuscinoses (Batten Disease). 2nd ed. Oxford, United Kingdom:Oxford University Press; 2011:80–109. 6. Williams RE et al. Management Strategies for CLN2 Disease. Pediatr Neurol 2017;69:102–112. 7. Nickel M et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health 2018;2(8):582–590. 8. Nickel M et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health 2018;2(8):582–590. Supplementary Material. 9. Worgall S et al. Hum Gene Ther 2008;19:463–474.